.png "Insmed (NASDAQ: INSM)")
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Insmed (NASDAQ: INSM), with a price target of $56. The company’s shares opened today at $25.10.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 32.9% and a 54.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
Insmed has an analyst consensus of Moderate Buy, with a price target consensus of $39.
See today’s analyst top recommended stocks >>
Based on Insmed’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $0 and GAAP net loss of $65.38 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $37.41 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.
